Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG-013958 in Wet Age-Related Macular Degeneration
NCT00090532Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Jan 2004
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of AG-013958 in exudative macular degeneration (3 arms), sponsored by Pfizer. Primary endpoint: Ocular and Systemic Safety. Started Jan 2004; status: terminated.
02
Drugs
AG-013958
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT00090532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00090532.